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Background: TomoBreast is a unicenter, non-blinded randomized trial comparing conventional radiotherapy (CR)
vs. hypofractionated Tomotherapy (TT) for post-operative treatment of breast cancer. The purpose of the trial is to
compare whether TT can reduce heart and pulmonary toxicity. We evaluate early toxicities.
Methods: The trial started inclusion in May 2007 and reached its recruitment in August 2011. Women with stage
T1-3N0M0 or T1-2N1M0 breast cancer completely resected by tumorectomy (BCS) or by mastectomy (MA) who
consented to participate were randomized, according to a prescribed computer-generated randomization schedule,
between control arm of CR 25x2 Gy/5 weeks by tangential fields on breast/chest wall, plus supraclavicular-axillary
field if node-positive, and sequential boost 8x2 Gy/2 weeks if BCS (cumulative dose 66 Gy/7 weeks), versus
experimental TT arm of 15x2.8 Gy/3 weeks, including nodal areas if node-positive and simultaneous integrated
boost of 0.6 Gy if BCS (cumulative dose 51 Gy/3 weeks). Outcomes evaluated were the pulmonary and heart
function. Comparison of proportions used one-sided Fisher's exact test.
Results: By May 2010, 70 patients were randomized and had more than 1 year of follow-up. Out of 69 evaluable
cases, 32 were assigned to CR (21 BCS, 11 MA), 37 to TT (20 BCS, 17 MA). Skin toxicity of grade ≥1 at 2 years was
60% in CR, vs. 30% in TT arm. Heart function showed no significant difference for left ventricular ejection fraction at
2 years, CR 4.8% vs. TT 4.6%. Pulmonary function tests at 2 years showed grade ≥1 decline of FEV1 in 21% of CR, vs.
15% of TT and decline of DLco in 29% of CR, vs. 7% of TT (P = 0.05).
Conclusions: There were no unexpected severe toxicities. Short course radiotherapy of the breast with
simultaneous integrated boost over 3 weeks proved feasible without excess toxicities. Pulmonary tests showed a
slight trend in favor of Tomotherapy, which will need confirmation with longer follow-up of patients.
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Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death in women,
accounting worldwide for 23% of total new cancer cases
and 14% of total cancer deaths in 2008 [1]. The past dec-
ades have seen advances in the diagnosis and treatment
of breast cancer, associated with a decrease of mortality
rate, although the changes vary widely between countries
[2,3]. Among treatments, adjuvant radiotherapy has
shown to improve local control and overall survival, with
a 70% proportional reduction of the risk of recurrence
[4] and a 9%–12% proportional reduction of the risk of
death [5–8]. Despite this established role of radiother-
apy, there are considerable disparities in the receipt of
radiotherapy that are attributable to various factors such
as limited availability of treatment centers, geographical
distance, long waiting times, and costs [9–11]. The dis-
parities can further be compounded by the long sche-
dules required with conventional radiotherapy, since the
schedules of radiotherapy that were evaluated in clinical
trials and were found to be associated with improved
survival are based on conventional fractionation of 1.8-
2.5 Gy/fraction, delivering treatment over 5 to 7 weeks
[5,8,12,13]. Many researches are actively investigating al-
ternative approaches. Intraoperative radiotherapy (IORT)
[14,15] or accelerated partial breast irradiation (APBI)
[16] provide the shortest schedules. However, IORT and
APBI are limited to selected cases of breast conservation
therapy [17]. Whole breast radiotherapy with a hypofrac-
tionated schedule delivering 42.5 Gy in 16 fractions over
22 days has been shown by the Ontario randomized trial
to be comparable with a conventional schedule of 50 Gy
in 25 fractions over 35 days [18]. However, boost radi-
ation was not used. The UK START trial A and trial B
found that 41.6 Gy in 13 fractions over 5 weeks or
40 Gy in 15 fractions over 3 weeks given after breast
conserving surgery (BCS) or after mastectomy (MA) had
outcomes on local control and adverse effects compar-
able to the conventional treatment of 50 Gy in 25 frac-
tions over 5 weeks [19,20]. A boost of 10 Gy in 5
fractions was allowed to centers that elected to give
boost, as well as regional radiotherapy to supraclavicular
nodes with or without axillary chains. The issue of boost
radiation was not addressed in the Ontario trial, for this
reason boost was given by conventional fractionation in
the UK START trials, reducing the gain in scheduling
time.
In the present study, we designed an experimental hypo-
fractionated schedule that would shorten overall treatment
time and be applicable to mastectomy patients as well as to
breast conservation patients by integrating a simultaneous
boost. The experimental treatment is compared with con-
ventional radiotherapy in a randomized clinical trial
(NCT00459628). The present study reports early toxicities.Methods
The primary outcome measure defined in the trial was
the change from baseline in pulmonary and heart func-
tion tests up to 3 years after treatment. The secondary
outcome measures were local-regional recurrences. The
trial started recruiting patients in May 2007. Eligible
patients were women aged 18 years or older, presenting
with histologically proven breast carcinoma, operated by
BCS or MA with clear margins, pathological stage T1-
3N0M0 or T1-2N1M0 [21]. Availability of at least one
pre-operative imaging by CT, MRI, and/or PET-scan was
required. Exclusion criteria were history of prior breast
or thoracic radiotherapy, pregnancy or lactation, absence
of effective contraception in fertile patients, psychiatric
or addictive disorders.
After written informed consent, patients were rando-
mized to either a control arm of conventional radiother-
apy (CR), or to the experimental arm of hypofractionated
Tomotherapy (TT). Randomization was balanced by nodal
status, type of surgery and chemotherapy sequence using
Efron's biased coin design [22].
In the control arm, a dose of 50 Gy was delivered in
25 fractions over 5 weeks to the chest wall (MA) or the
whole breast (BCS) by 6 or 15 MV photons tangential
wedged fields and using field-in-field multileaf compen-
sation when doses exceed 110%, and to the supraclavicu-
lar, infraclavicular and axillary nodes in case of pN1
status, using an anterior 6 MV photons half-beam
matched to the superior border of the tangential fields.
The field borders were set clinically. The typical tangen-
tial field borders were: superior just below the clavicle
head, inferior 1.5 cm below the infra-mammary crease
or the lower part of the ipsilateral breast (BCS) or the
contralateral breast (MA), medial at mid-sternum and
lateral at the mid-axillary line (pN0) or at the anterior
border of the scalene muscles (pN1). The borders of the
supraclavicular field were: superior caudal to the cricoid
cartilage, inferior at the caudal edge of the clavicle head,
medial excluding the trachea and lateral at the junction
of the first rib with the clavicle. Breast conserved
patients received an additional boost of 16 Gy in 8 frac-
tions over 2 weeks to the initial tumor bed using a direct
electron field, i.e. a cumulative dose of 66 Gy in 33 frac-
tions over 7 weeks at the tumor bed. No dose con-
straints for lung and heart were defined in the
conventional arm, but the perpendicular distance from
the chest wall to the posterior field edge preferably
included no more than 2 cm of lung at any point along
the length of the tangent. This lung distance was not to
exceed 3 cm. For left-sided breast radiotherapy, the max-
imum heart distance was not to exceed 1.5 cm. The
boost volume was aligned taking into account the pre-
operative imaging (mammography and CT, MRI or PET)
and post-operative changes (scar, seroma) seen on the
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7 mm was used. Often surgical clips at the borders of
the operation area were available. These clips were to be
inside the CTV. CTV to planning target volume (PTV) -
margin was 5 mm.
In the experimental arm, patients were treated using
the Helical TomoTherapyW Hi-art system [23] (Madison,
US). A total dose of 42 Gy in 15 fractions over 3 weeks
was prescribed to the same target volumes as the con-
ventional arm: chest wall in case of MA or whole breast
in case of BCS, and to the supraclavicular, infraclavicular
and axillary nodes in case of pN1 status. In case of BCS,
a simultaneous integrated boost (SIB) of 0.6 Gy per frac-
tion was prescribed to the tumor bed, i.e. a dose of
51 Gy in 15 fractions over 3 weeks at the tumor bed.
The boost volume was aligned as for the conventional
radiotherapy, with the same CTV and PTV margins.
Tomotherapy dose specifications for target volumes
breast/chest wall, boost, and lymph node regions were
to receive 95%–105% of prescribed dose. Dose con-
straints for heart and ipsilateral lung were respectively
V5Gy< 10% and V17Gy< 7%, contralateral breast
V10Gy< 5%.
Per protocol, radiotherapy in any arm started within
6 weeks after breast surgery. In case of sequential adju-
vant treatment with chemotherapy first, radiotherapy
started after a delay of 2 weeks, but within 6 weeks after
completion of adjuvant chemotherapy. Concomitant
chemotherapy was allowed.
Pulmonary and heart function, arm mobility and arm
lymphedema were assessed prior to radiotherapy, at 2 (±
1) months after completion of radiotherapy and there-
after yearly for 3 years. Heart function was assessed by
measuring the left ventricular ejection fraction (LVEF)
by echocardiography. Pulmonary function tests assessed
forced expiratory volume in one second (FEV1) and dif-
fusing capacity of the lung for carbon monoxide (DLco).
Heart and lung toxicity scoring was based on the com-
mon terminology criteria of adverse events (CTCAE) v.3
[24]. Scoring of breast/chest wall skin and subcutaneous
toxicity used the Radiation Therapy Oncology Group
(RTOG) acute (up to 1 month post radiotherapy) and
late (after 1 month) morbidity scoring schemas [25].
Scoring of arm lymphedema used the SOMA/LENT tox-
icity scale [26].
The planned accrual was to recruit 118 patients, based
on a power of 0.80 to detect a 5% vs. 25% incidence of
all heart and lung toxicities between the two treatment
arms. The trial closed for inclusion in August 2011. A
total of 123 patients were randomized after giving
informed consent. The present report concerns the first
70 patients enrolled up to August 2009, having a min-
imal follow-up time of 1 year. The follow-up cut-off date
was May 2011. Data were analyzed by intention to treat.Comparison of proportions used Fisher's exact test, one-
sided. Statistical computations used JMP v. 8.0.1 (SAS
Institute Inc, Cary, NC, USA). The trial was accepted by
the ethical committee of the UZ Brussel.
Results
Of the 70 women with more than 1 year follow-up, 1 pa-
tient was not eligible due to bilateral breast carcinoma,
leaving 69 patients available for the present study. Thirty
two were randomized to CR, 37 to TT. Two patients
allocated to CR refused conventional treatment and were
subsequently treated by TT. One patient allocated to TT
could not be positioned on the Tomotherapy couch be-
cause of extreme obesity, she was treated by CR.
The mean age of the study participants was 55 years
(range 32--78 years) (Table 1). There was a non-
significant preponderance of left sided tumors, 58% (40
of 69). A medial tumor location was observed in 29%
(20 of 69) patients. Breast conserving surgery was per-
formed in 59% (41 of 69) patients. Axillary surgery was
by sentinel nodes biopsy alone in 54% (37 of 69), senti-
nel nodes biopsy followed by completion axillary lymph
node dissection in 14% (10 of 69), and axillary lymph
node dissection by first intent in 32% (22 of 69). The
pathological mean tumor size was 17 mm (range 2--
42 mm). Multifocality was noted in 14% (10 of 69)
patients. The majority of patients were node negative,
65% (45 of 69). The mean lymph node ratio (LNR)
among node-positive patients was 0.13 (range 0.04–
0.33). Using cut-offs of 0.20 and 0.65 [27], 79% (19 of
24) of the node-positive patients had a low LNR, 21% (5
of 24) had an intermediary LNR, and no patient had a
high LNR. The frequencies of estrogen receptor positiv-
ity, progesterone receptor positivity, and HER2 FISH
amplification were 80% (55 of 69), 67% (46 of 69), and
14% (10 of 69), respectively. A high histological grade
was observed in 26% (18 of 69) patients. Adjuvant
chemotherapy was given to 49% (34 of 69) patients.
Among patients receiving adjuvant chemotherapy, most
had chemotherapy scheduled to start concomitantly with
radiotherapy, 76% (26 of 34), i.e. 38% of all patients. Ad-
juvant hormone therapy was given to 80% (55 of 69) and
trastuzumab to 14% (10 of 69) patients.
The distribution of the patients' characteristics by age,
laterality, tumor location, type of surgery, histopath-
ology, hormone receptor status, tumor size, lymph node
positivity and ratio, adjuvant chemotherapy and hor-
mone therapy were comparable between the two
randomization arms (Table 1).
Figure 1 shows the average dose volume histograms
(DVH) for the breast/chest wall (CTV1), the lymph node
areas (CTVn), the contralateral breast, the ipsilateral lung
for all patients and the heart for left sided irradiation. This
shows a more homogeneous coverage of the CTV1 and





>= 50 22 22
Left breast tumor 16 24
Medial location 12 8
Tumor size
T1 (<= 20 mm) 21 26
T2 (21–50 mm) 11 11
Nodal status, Lymph node ratio
pN0 21 24
pN1, LNR 0.01-0.20 7 12
pN1, LNR 0.21-0.65 4 1
pN1, LNR> 0.65 0 0
Estrogen receptor positive 28 27
Progesterone receptor positive 21 25







Breast conserving 21 20
Axillary lymph nodes
Sentinel biopsy only 20 17
Sentinel with axillary dissection 4 6
Immediate axillary dissection 8 14
Radio-chemotherapy schedule
No adjuvant chemotherapy 18 17
RT after completion of chemotherapy 3 5
RT concomitant with start chemotherapy 11 15
Chemotherapy type
Anthracycline without taxane 3 4
Anthracycline with taxane 10 15
CMF 1 1
Hormone therapy




Tamoxifen+ Zoladex 0 4
Trastuzumab 2 8
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CTV and not the PTV data, because no PTV is made for
the conventional treatment, since the borders of the ir-
radiation field for this group are chosen according toclinical landmarks. A small margin is allowed in the
Tomotherapy group, since daily megavolt CT imaging is
performed before every treatment session. Notice the tail
in the CTV1 of the Tomotherapy group. This is explained
by the dose gradient from the CTV1 to the boost volume
(CTVb). This is not present in the conventional therapy,
because the boost in this group is given after the end of
the whole breast irradiation. This additional boost is given
with electrons. Our planning system does not allow a dose
calculation for electrons. This means that the DVHs for
the conventional therapy lack part of the actual received
dose. Even so there is fewer dose to the heart and ipsilat-
eral lung with Tomotherapy. The average dose on the heart
is 7.1 Gy±5.7 Gy (CR), 1.7 Gy±2.5 Gy (TT), on the ipsilat-
eral lung is 6.6 Gy±12.0 Gy(CR) and 4.7 Gy±7.5 Gy (TT).
A higher dose is delivered on the contralateral breast with
Tomotherapy compared to the conventional treatment
(average dose CR: 0.3 Gy±0.5 Gy vs. TT: 2.6 Gy±2.3 Gy).
These findings are in line with the results of a planning
study we performed earlier [23].
The median follow-up of all patients was 28 months
(range 16--48 months). No patient died during follow-up.
There was no local recurrence or new primary breast
tumor. One patient in the control arm was diagnosed with
bone metastases 2 months after randomization. A second
primary tumor was diagnosed in 3 patients in the control
arm (1 skin basal cell carcinoma of the nose, 1 kidney car-
cinoma, 1 sigmoid carcinoma) and in 1 patient in the
Tomotherapy arm (1 lung adenocarcinoma) (P=0.3).
All patients completed radiotherapy. Mean treatment
duration was 43 days (range 20--54) in the conventional
arm, 22 days (range 18--36) in the Tomotherapy arm. At
completion and up to 1 month after radiotherapy, the clin-
ical evaluation and RTOG acute scoring found skin toxicity
grade 0 in 6.25% (2 of 32), grade 1 in 65.6% (21 of 32),
grade 2 in 21.9% (7 of 32), and grade 3 in 6.25% (2 of 32) of
patients in the control arm; grade 0 in 5.4% (2 of 37), grade
1 in 59.5% (22 of 37), grade 2 in 27.0% (10 of 37), grade 3 in
8.1% (3 of 37) in the Tomotherapy arm (P Chi-square=
0.94). Peak erythema occurred at the end of treatment in
the conventional arm and at 10 to 14 days after end of
treatment in the Tomotherapy arm.
Table 2 summarizes toxicities observed from 2 months
up to 2 years. We pooled all toxicities of grade 1 or
higher as compared with pre-radiotherapy baseline. At
2 years, patients in CR had twice more persistent skin
change than patients in the TT, 60% (12 of 20 patients)
vs. 30% (6 of 20 patients), P = 0.06. The frequencies of
breast/chest wall fibrosis, arm lymphedema and heart
toxicity (LVEF) were comparable between the two
randomization arms. Lung function tests showed a sig-
nificant reduction of lung toxicity in TT based on
changes of DLco, P = 0.047, but not based on changes of
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Figure 1 Dose volume histogram. The average dose volume
histograms (DVH) of the CTV's and the most important organs at risk
are shown for CR and TT. The average DVH for the heart was
generated for left sided irradiation only. The dose is formulated in
2 Gy equivalent dose (EQ2) with an alpha/beta of 3 Gy.
Van Parijs et al. Radiation Oncology 2012, 7:80 Page 5 of 10
http://www.ro-journal.com/content/7/1/80patients who had G1 or higher lung toxicity based on
DLco, which showed consistent over time, compared to
the average DVH. The individual DVHs are positioned
above, as well as below the average DVH. In the situ-
ation that the observed lung toxicity would be closely
related to the delivered lung dose, one would expect all
the individual DVHs above the average DVH. Among
these 9 women 7 were treated with concomitant chemo-
therapy, of which 3 were irradiated on the lymph node
regions. A boost dose was delivered in 4 women. Three
women had a smoking history. One woman had known
asthma.
Discussion
A meta-analysis performed in our department, using data
of the Early Breast Cancer Trialists' Cooperative Group
(EBCTCG), argued that trials showing a survival benefit
were the more recent trials using current techniques [5].
Considering that the survival advantage with adjuvant
radiotherapy was confirmed [6,28], the question that arises
is whether or not breast cancer could further benefit from
more advanced radiotherapy techniques. There are how-
ever two obstacles against the implementation of image
guided radiotherapy (IGRT) for breast cancer patients.
One obstacle is that IGRT is labor intensive. Priority to
implement IGRT is given to the treatment of tumor con-
ditions in which adverse reactions can be severe and de-
bilitating, such as lung cancer, digestive or head and neck
tumors [29,30]. The other obstacle is the controversy on
whether IGRT could improve over simpler variants of tan-
gential fields [31]. There is thus a need to prospectively as-
sess the benefit of IGRT for breast cancer patients.
The earlier mentioned meta-analysis also argued that a
survival benefit was shown in trials using a standard
fractionation between 1.8 Gy and 2.5 Gy per fraction [5].
Since then, there has been growing evidence on the ap-
plicability of hypofractionation for adjuvant radiotherapy
of breast cancer, as shown in Table 3. A natural exten-
sion is therefore to combine hypofractionation with
IGRT in order to improve the availability of IGRT to
breast cancer patients. Our clinical trial is the first to
compare an integrated strategy of hypofractionated
IGRT, versus a strategy of conventional radiotherapy.
Our choice of fractionation of 42 Gy to whole breast and
boost to 51 Gy in 15 fractions took into account that our
institution's standard conventional radiotherapy is 50 Gy to
whole breast and boost to 66 Gy. In the IMPACT HIGH
trial, the schedule in 15 fractions is to deliver 36 Gy to





















at 2 months 32 65.6 21 36 24 66.7 0.636
at 1 year 31 14 45.2 36 14 38.9 0.393
at 2 years 20 12 60.0 20 6 30.0 0.056
Breast/chest wall fibrosis
at 1 year 32 12 37.5 36 10 27.8 0.276
at 2 years 24 9 37.5 24 6 25.0 0.267
Arm lymphedema
at 2 months 32 2 6.2 36 1 2.8 0.455
at 1 year 32 2 6.2 36 2 5.6 0.647
at 2 years 24 3 12.5 24 3 12.5 0.667
Heart function
at 2 months 32 9 28.1 35 4 11.4 0.078
at 1 year 31 4 12.9 36 8 22.2 0.906
at 2 years 21 1 4.8 22 1 4.6 0.744
Lung toxicity score based on change in FEV1 (*)
at 2 months 30 4 13.3 34 3 8.8 0.429
at 1 year 29 4 13.8 34 4 11.8 0.552
at 2 years 24 5 20.8 27 4 14.8 0.422
Lung toxicity score based on change in DLco (*)
at 2 months 30 10 33.3 34 8 23.5 0.277
at 1 year 29 8 27.6 34 3 8.8 0.052
at 2 years 24 7 29.2 27 2 7.4 0.047
Lung toxicity based on change in FEV1 and DLco (*)
at 2 months 30 12 40.0 34 10 34.3 0.266
at 1 year 29 12 41.4 34 6 28.6 0.036
at 2 years 24 10 41.7 27 5 22.2 0.066
(*) Cases who did not receive RT according to randomization arm were computed as missing.
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53 Gy, which based on an alpha/beta of 3 Gy would corres-
pond to conventional schedule of 40 Gy whole breast and
boost to 60 Gy - 69 Gy [38].
Table 3 shows how our study compares with other clin-
ical trials. We are aware of several controversial issues,
notably regarding post-mastectomy radiotherapy for
node-negative patients and for node-positive patients with
less than 4 nodes involved. We have argued that these
patients did derive a survival benefit [39,40] and have
maintained the treatment of nodal areas in node-positive
patients regardless of the number of involved nodes. Most
recently, results from the MA 20 trial confirmed that re-
gional nodal irradiation prolonged disease free survival for
women with one to three involved nodes [41].Another controversial issue is the high number of
patients treated by concomitant chemo-radiotherapy.
One randomized trial found a significantly better loco
regional recurrence free survival with a concomitant ap-
proach in node-positive breast cancer, with an accept-
able increase in toxicity [42,43]. More data with current
chemotherapy regimens, including taxanes, will need to
be accrued.
There is the issue of delivering a simultaneous integrated
boost, giving an even higher daily dose to the tumor bed.
We could show this did not deliver a higher dose to the
organs at risk. This technique could prove advantageous by
even delivering less total dose to the surrounding breast tis-
sue [44], though this was not analyzed in detail. Longer fol-
low up is needed to compare the long term side effects.







6 - - + - - 
11 - + + +  
(5) 
-
31 - + + - - 
57 + - + stopped  
(30)
-
3 - - + - - 
17 + - - - - 
19 + - - - + 
21 - - + stopped  
(5) 
-
22 + + + - - 
Figure 2 DVHs of the ipsilateral lung for patients who showed consistent DLco-decrease of >10%. The individual DVHs for the patients
who had G1 or higher lung toxicity based on DLco, which proved consistent over time, are shown compared to the average DVH for TT and CR.
The dose is formulated in 2 Gy equivalent dose (EQ2) with an alpha/beta of 3 Gy.
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ences that arise between the treatment arms cannot be
unequivocally attributed to fractionation or to technique.
A 2x2 design would have been conceptually more satis-
fying, but was practically unfeasible.
Regarding the trial's primary endpoint, the results
showed a trend of reduced lung toxicities but not signifi-
cant enough to warrant early stopping of the trial. No ex-
cess toxicities were found in the Tomotherapy arm, whichargues that hypofractionation with simultaneous integrated
boost is feasible, when using IMRT-IGRT. This can have
important implication regarding availability and accessibil-
ity of advanced radiotherapy techniques to more patients.
Hypofractionation not only is more convenient for the
patients by limiting the number of treatment attendances,
it can reduce waiting times for adjuvant radiation therapy
and possibly impact on survival [45]. Shorter schedules can
have an important socio-economic impact by lowering
Table 3 Randomized clinical trials of hypofractionated whole breast/chest wall radiotherapy























3.3 Gy x 13 F/ 5 No No Yes NS No =
weeks




1998- 2236 3 Gy x 13 F/ 5 No Yes Yes NS Yes More local
relapses
2002 weeks
UK Start A 3.2 Gy x 13 F/ 5 No Yes Yes NS Yes =
weeks
Lahore [34] 1998- 300 5.4 Gy x 5 F/ 1 No Yes Yes NS Yes =
2004 week
Lahore 3.5 Gy x 10 F/ 2 No Yes Yes NS Yes =
weeks
Lahore 2.66 Gy x 15 F/ 3 No Yes Yes NS Yes Control arm
weeks
UK Start B [20] 1999- 2215 2.67 Gy x 15 F/ 3 No Yes Yes NS Yes =
2001 weeks
Egypt NCI [35] 2002- 30 2.66 Gy x 16 F/ 3 No No No NS No Boost in
conventional arm
2003 weeks
UK FAST [36] 2004- 915 5.7 Gy x 5 F/ 5 ? No No Yes No =
2007 weeks













2.4 Gy [SIB 3.53
Gy]
Yes No ? Yes ?
x 15 F/
UZ Brussel 2007- 122 2.8 Gy [SIB 3.4 Gy] Yes Yes Yes Yes Yes Closed for
inclusion; FU
on-going[this study] x 15 F/ 3 weeks
(*) Partial report; full study 1982–1989, n = 525 patients. (**) Planned accrual.
NS: not stated. =: outcome comparable with control arm. SIB: simultaneous integrated boost. FU: follow-up.
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personnel and machine time [46]. An increase in costs can
be expected due to the more labor intensive preparation of
a Tomotherapy treatment and a longer daily machine time
for treatment delivery and related quality assurance. But
the most important determinant of the cost of radiotherapyis the total number of fractions. A favorable balance can be
expected for the hypofractionated schedule.
Conclusions
The present analysis shows that hypofractionation with
simultaneous integrated boost is feasible, when using
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http://www.ro-journal.com/content/7/1/80IMRT-IGRT, without excess toxicities. There is a trend of
reduced lung toxicity in the hypofractionated arm.
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